Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Huntington National Bank

Huntington National Bank lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 11.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 194,928 shares of the medical research company’s stock after selling 26,219 shares during the quarter. Huntington National Bank’s holdings in Edwards Lifesciences were worth $14,431,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $30,000. Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $54,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $72.09 on Thursday. The stock has a market capitalization of $42.38 billion, a P/E ratio of 10.34, a P/E/G ratio of 4.82 and a beta of 1.15. The business has a 50-day moving average of $71.65 and a two-hundred day moving average of $70.60. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,553 shares of company stock worth $4,513,064 in the last quarter. 1.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Citigroup lifted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.